JNJ-101556143

DRUG2 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Metastatic Castration-resistant Prostate NeoplasmsMetastatic Hormone-sensitive Prostate CancerProstatic Neoplasms

Phase 1

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

RecruitingNCT05818683

Janssen Research & Development, LLCMetastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer

Start: 2023-04-26End: 2028-05-23Target: 300Updated: 2026-05-08

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

RecruitingNCT06095089

Janssen Research & Development, LLCProstatic Neoplasms

Start: 2023-11-01End: 2028-06-28Target: 355Updated: 2026-05-04